Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Sulbactam Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 134Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4ENTASIS THERAP

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    ENTASIS THERAP

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    arrow
    Immuno-Oncology 360
    Not Confirmed

    ENTASIS THERAP

    U.S.A
    arrow
    Immuno-Oncology 360
    Not Confirmed

    Patent Expiration Date : 2035-11-17

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    US Patent Number : 10376499

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 216974

    Patent Use Code : U-2840

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2035-11-17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ENTASIS THERAP

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    arrow
    Immuno-Oncology 360
    Not Confirmed

    ENTASIS THERAP

    U.S.A
    arrow
    Immuno-Oncology 360
    Not Confirmed

    Patent Expiration Date : 2035-11-17

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    US Patent Number : 9968593

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 216974

    Patent Use Code : U-2840

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2035-11-17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ENTASIS THERAP

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    arrow
    Immuno-Oncology 360
    Not Confirmed

    ENTASIS THERAP

    U.S.A
    arrow
    Immuno-Oncology 360
    Not Confirmed

    Patent Expiration Date : 2033-04-02

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    US Patent Number : 9623014

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 216974

    Patent Use Code : U-2840

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-04-02

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    ENTASIS THERAP

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    arrow
    Immuno-Oncology 360
    Not Confirmed

    ENTASIS THERAP

    U.S.A
    arrow
    Immuno-Oncology 360
    Not Confirmed

    Patent Expiration Date : 2033-04-02

    DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

    US Patent Number : 9309245

    Drug Substance Claim : Y

    Drug Product Claim :

    Application Number : 216974

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-04-02

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF